Using B7-H3 CAR T cells after radiation to treat a deadly brain tumor in children and young adults

Who could benefit from this research

What this research studies

This research investigates the use of B7-H3 CAR T cells in children and young adults diagnosed with diffuse intrinsic pontine glioma (DIPG), a highly aggressive brain tumor. The approach involves administering these engineered immune cells after the patients have received initial radiation therapy, aiming to improve survival rates. The study builds on previous findings that showed promising results in a first-in-human trial, where patients treated with CAR T cells had a longer median overall survival compared to historical data. Patients will be monitored closely, and advanced imaging techniques will be used to assess treatment efficacy and identify biomarkers.

Why it matters

Where this research is happening

• Seattle Children's Hospital
  Seattle, United States Active

Researchers

• Principal investigator: Vitanza, Nicholas a — Seattle Children's Hospital
• Study coordinator: Vitanza, Nicholas a

Related research

Other NIH-funded projects on the same topics.

• B7-H3 CAR T cells after initial radiation for children and young adults with DIPG

  A new treatment approach uses B7-H3 CAR T cells after initial radiation to help children and young adults with diffuse intrinsic pontine glioma feel better and live longer.

  NIH research Seattle Children's Hospital · Seattle, United States · NIH-11335575

• Targeting the ATIC enzyme in diffuse intrinsic pontine glioma (DIPG)

  Researchers are testing ways to block a metabolic enzyme called ATIC to try to slow or stop aggressive DIPG tumors in children.

  NIH research Emory University · Atlanta, United States · NIH-11233309

• Investigating a new treatment target for a deadly childhood brain cancer

  This study is looking at a new way to fight a tough brain cancer called DIPG in kids by targeting a specific molecule that might help the tumors grow, with hopes of finding better treatments to help these children.

  NIH research Emory University · Atlanta, United States · NIH-11191212

• Peptide vaccine targeting CMV for children with high-grade glioma, DIPG, and recurrent medulloblastoma

  This vaccine trains the immune system to target a viral protein (CMV pp65) that is often found in certain pediatric brain tumors to help slow or shrink the tumor.

  NIH research Duke University · Durham, United States · NIH-11177623

• Using targeted therapy to treat a deadly brain tumor in children

  This study is testing a new treatment for children with a tough brain tumor called DIPG, using special molecules to target a specific gene mutation in the tumor, with the hope of helping kids live longer and healthier lives.

  NIH research State University New York Stony Brook · Stony Brook, United States · NIH-11099689

• Targeting a specific mutation in brain tumors with RNA nanoparticles

  This study is testing a new treatment for kids with Diffuse Intrinsic Pontine Glioma (DIPG), a tough-to-treat brain tumor, by using special mRNA vaccines that help the immune system fight the cancer, and it hopes to eventually help children with this condition.

  NIH research University of Florida · Gainesville, United States · NIH-10951747

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.